| Literature DB >> 24391351 |
M G Wiggans1, S Fisher2, H Adwan2, S Aroori2, M J Bowles2, D A Stell1.
Abstract
Introduction. Reducing the volume of resected liver parenchyma may lead to lower morbidity and mortality. The aim of this study was to determine whether partial preservation of segment IV leads to improved outcomes when undertaking extended right hepatectomy for colorectal liver metastases (CRLM). Materials and Methods. A retrospective analysis of patients undergoing right-sided hepatectomy for CRLM was performed. Rates of 90-day mortality and organ dysfunction were compared in 117 patients undergoing right hepatectomy (n = 85), partially extended right hepatectomy with preservation of part of segment IV (n = 20), and fully extended right hepatectomy (n = 12). Results. The 90-day mortality rate of those undergoing right hepatectomy (3/85) was similar to that of those undergoing extended right hepatectomy (0/12) (P = 1.000) but lower than that of those undergoing partially extended right hepatectomy (4/20) (P = 0.024). The rates of hepatic and renal dysfunction were similar between patients undergoing right hepatectomy, partially extended or extended hepatectomy. Discussion. Preservation of part of segment IV confers little clinical benefit when performing extended right hepatectomy for CRLM.Entities:
Year: 2013 PMID: 24391351 PMCID: PMC3874357 DOI: 10.1155/2013/458641
Source DB: PubMed Journal: HPB Surg ISSN: 0894-8569
Patient characteristics, operative details, and outcomes for 117 patients undergoing right-sided hepatectomy for colorectal liver metastases.
|
| Operation |
| ||||||
|---|---|---|---|---|---|---|---|---|
|
Right hepatectomy |
Partially extended right |
Extended right | ||||||
| Count (%) | Median (range) | Count (%) | Median (range) | Count (%) | Median (range) | Partially extended versus right | Extended right versus right | |
| Age | 65 (33–82) | 66 (40–88) | 61 (54–77) | 0.899 | 0.354 | |||
| Gender | ||||||||
| Female | 35 (41.2) | 7 (35.0) | 5 (41.7) | 0.800 | 1.000 | |||
| Male | 50 (58.8) | 13 (65.0) | 7 (58.3) | |||||
| T stage of primary | ||||||||
| 0 | 1 (1.2) | 1 (5.0) | 0 | 0.326 | 1.000 | |||
| 1 | 2 (2.4) | 0 | 0 | 1.000 | 1.000 | |||
| 2 | 4 (4.7) | 2 (10.0) | 2 (16.7) | 0.290 | 0.144 | |||
| 3 | 48 (56.5) | 12 (60.0) | 6 (50.0) | 0.600 | 1.000 | |||
| 4 | 28 (32.9) | 3 (15.0) | 3 (25.0) | 0.258 | 1.000 | |||
| N/A* | 2 (2.4) | 2 (10.0) | 1 (8.3) | — | — | |||
| N stage of primary | ||||||||
| 0 | 39 (45.9) | 7 (35.0) | 3 (25.0) | 0.608 | 0.335 | |||
| 1 | 21 (24.7) | 7 (35.0) | 6 (50.0) | 0.257 | 0.072 | |||
| 2 | 23 (27.1) | 4 (20.0) | 2 (16.7) | 0.774 | 0.721 | |||
| N/A* | 2 (2.4) | 2 (10.0) | 1 (8.3) | — | — | |||
| Preoperative Chemotherapy | ||||||||
| Yes | 50 (58.8) | 10 (50.0) | 9 (75.0) | 0.616 | 0.356 | |||
| No | 35 (41.2) | 10 (50.0) | 3 (25.0) | |||||
| Number of chemotherapy cycles | 4 (2–11) | 4 (1–4) | 5 (1–6) | 0.115 | 0.854 | |||
| Synchronous bowel resection | 1 (1.2) | 0 | 1 (8.3) | 1.000 | 0.233 | |||
| Number of tumours | 1.5 (1–9) | 2 | 2.5 | 0.100 | 0.118 | |||
| Maximum diameter (mm) | 35 | 50 | 52.5 | 0.026† | 0.004† | |||
| Pringle manoeuvre used | 0 | 1 (5.0) | 0 | 0.191 | 1.000 | |||
| Blood loss | ||||||||
| <500 mL | 43 (50.6) | 5 (25.0) | 4 (33.3) | 0.046† | 0.357 | |||
| >500 mL | 41 (48.2) | 15 (75.0) | 8 (66.7) | |||||
| Not recorded | 1 (1.2) | 0 | 0 | |||||
| Postoperative lactate (mmol/L) | 3.3 | 3.35 | 4.35 | 0.592 | 0.006† | |||
| Bile leak | 7 (8.2) | 2 (10.0) | 2 (16.7) | 0.680 | 0.308 | |||
| Renal dysfunction (POD 0–5) | ||||||||
| Yes | 10 (11.8) | 3 (15.0) | 0 | 0.710 | 0.355 | |||
| No | 75 (88.2) | 17 (85.0) | 12 (100) | |||||
| Peak postoperative transaminase (iu/L) | 376 | 435 | 309 | 0.356 | 0.289 | |||
| PHLF on POD 5 | ||||||||
| Yes | 13 (15.3) | 4 (20.0) | 1 (8.3) | 0.508 | 1.000 | |||
| No | 72 (84.7) | 15 (75.0) | 11 (91.7) | |||||
| N/A** | 1 (5.0) | |||||||
| Length of stay (days) | 8 (4–30) | 8 (6–27) | 8 (5–15) | 0.613 | 0.629 | |||
| 90-day mortality | ||||||||
| Yes | 3 (3.5) | 4 (20.0) | 0 | 0.024† | 1.000 | |||
| No | 82 (96.5) | 16 (80.0) | 12 (100) | |||||
| Death from liver failure | ||||||||
| Yes | 2 (2.4) | 3 (15.0) | 0 | 0.047† | 1.000 | |||
| No | 83 (97.6) | 17 (85.0) | 12 (100) | |||||
*Primary pathology not available for 5 patients. **PHLF not applicable if patient died before POD 5. †Significant at the level of P < 0.05.